Iambic Therapeutics · 公司檔案

公開已核驗進展

1. Iambic 提交第二款自有 AI 发现候选药 IAM217 的 IND

   Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據

   据 Iambic 官方公告，已提交 IAM217 的 IND 申请。提交申请不等于监管批准，也不代表临床疗效已获证实。

   Iambic Therapeutics

   核查事件證據 →

2. Iambic 与 AbbVie 宣布 AI 药物发现合作

   Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據

   据双方在 Iambic 官网发布的公告，将利用 Iambic 的 AI 平台合作开展药物发现，提高候选药物识别效率。属于公司宣布的合作，未独立验证研发成效。

   艾伯维 · Iambic Therapeutics

   核查事件證據 →

3. Iambic 与拜耳合作推进 AI 小分子发现

   Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據

   据 Iambic 官方公告，拜耳将通过合作使用 Iambic 的 AI 平台开展新药发现；尚非临床疗效结论。

   拜耳制药 · Iambic Therapeutics

   核查事件證據 →

合作、許可與並購時間線

1. Iambic 与 AbbVie 宣布 AI 药物发现合作

   Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據

   据双方在 Iambic 官网发布的公告，将利用 Iambic 的 AI 平台合作开展药物发现，提高候选药物识别效率。属于公司宣布的合作，未独立验证研发成效。

   艾伯维 · Iambic Therapeutics

   核查事件證據 →

2. Iambic 与拜耳合作推进 AI 小分子发现

   Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據

   据 Iambic 官方公告，拜耳将通过合作使用 Iambic 的 AI 平台开展新药发现；尚非临床疗效结论。

   拜耳制药 · Iambic Therapeutics

   核查事件證據 →

以上來自最新 3 條已核驗進展。合作事件成立與模型效果、實驗結果或臨床進度分別需要證據。

公開原文線索

• Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate

  Iambic official newsroom · 行業原文收錄 · 來源發佈：Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:58 GMT+0000 (Coordinated Universal Time)

  In nonclinical studies, IAM217 was observed to have potent and selective target engagement with a favorable drug-drug interaction profile IAM217 is believed to be brain penetrant, producing regression of established intr

  原始出處

• AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

  Iambic official newsroom · 行業原文收錄 · 來源發佈：Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:23 GMT+0000 (Coordinated Universal Time)

  − Multi-year partnership applies Iambic’s AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology − Companies to pursue programs with both first-in-class and best-in-class potential

  原始出處

• Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development

  Iambic official newsroom · 行業原文收錄 · 來源發佈：Mon Sep 21 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:09 GMT+0000 (Coordinated Universal Time)

  Enchant v3 is the next generation of Iambic’s multimodal transformer model, trained using 41 billion parameters on more than 6,000 molecular properties across 16 biomedical data modalities Enchant v3 ingests diverse data

  原始出處

• Bayer and Iambic collaborate to advance drug discovery with AI

  Iambic official newsroom · 行業原文收錄 · 來源發佈：Mon Jun 22 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:35 GMT+0000 (Coordinated Universal Time)

  Bayer and Iambic collaborate to advance drug discovery with AI Collaboration focuses on small molecule discovery Bayer to leverage Iambic’s AI platform to address hard-to-drug targets Collaboration will strengthen Bayer’

  原始出處

• Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

  Iambic official newsroom · 行業原文收錄 · 來源發佈：Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:47 GMT+0000 (Coordinated Universal Time)

  San Diego, CA – May 19, 2026 – Iambic is a CNBC Disruptor 50 for the second year in a row, joining the ranks of repeat Disruptors OpenAI, AirBnB, and SpaceX. The Disruptor 50 is an annual list curated by CNBC to recogniz

  原始出處

已驗證的官方與訂閱來源

• Iambic official newsroom · 採集已啓用 · 最近成功 Fri Oct 09 2026 07:09:11 GMT+0000 (Coordinated Universal Time)

來源驗證與持續採集分別顯示；原文收錄不自動成為已核驗事件。